Brief: Pharvaris To Highlight Positive Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks At AAAAI Annual Meeting
24/02/2023 11:55
Feb 24 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS TO HIGHLIGHT POSITIVE PHASE 2 DATA FROM RAPIDE-1
STUDY
OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS AT AAAAI
ANNUAL MEETING
Source text for Eikon: ID:nGNX86024z
Further company coverage: PHVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal